The Green Cross Corporation

Taisho Pharmaceutical Co., Ltd.

Ishihara Sangyo Kaisha, Ltd.

Tanabe Seiyaku Company, Limited

Kaken Pharmaceutical Company, Ltd.

Tadakazu Suyama

Kazumasa Yokoyama

Chikara Fukaya

Taizo Ono

Yoshio Arakawa

Yoshio Tsuda

Youichiro Naito

Yoshihisa Inoue

Yahiro Uemura

Hirofumi Arimura

Satoshi Funakoshi

Yutaka Mizushima

Masayuki Nishida

Yoshiro Iga

Yoshio Kagitani

Hiroyuki Okamoto

Hiroshi Morise

Yusei Shiraga

Yasuo Ueda

Haruhide Kawabe

Takao Ohmura

Masahiro Watanabe

Katsuhiro Uchida

Katuhiro Uriyu

Masakazu Iwai

Toshiaki Akira

Masao Tohno

Susumu Otomo

Kanemichi Okano

Tsunekazu Fukushima

Hiromichi Mukai

Hironaka Aihara

Hajime Horii

Kiichiro Nabeta

Mamoru Tabata

Hiroshi Fukui

Shigeo Tanaka

Muneo Tsujikawa

Kenji Tanaka

Takahiro Haga

Kaoru Kobayashi

Toru Koyanagi

Nobutoshi Yamada

Hideo Sugi

Kazuo Takechi

Akinori Sumi

Yutaka Hirao

Wataru Ohtani

Yoshinobu Hashimoto

Makoto Okumura

Tsunetaka Nakajima

Nobuo Kondo

Ryozo Watanabe

Nobuhiko Komatsu

Masanori Sugiura

Hideo Nishimaki

Daisuke Satoh

Akimasa Ohmizu

Takashi Kobayashi

Kiyonoshin Ichikawa

Masanori Nagai

Tsuyoshi Takahashi

Ryoichi Naito

Noboru Yamada

Takashi Goto

Satoshi Morimoto

Shigetoshi Sugio

Koichi Yamauchi

Kazumoto Hirabayashi

Eiji Sako

Kazumi Fukuyama

Midori Nagatomo

Ryutaro Yamana

Takeshi Yamauchi

Tsutomu Kitagawa

Yoshiaki Kanou

Tunetaka Nakajima

Takuji Doi

Tomokuni Taniguchi

Mitsugu Fujii

Shozoh Masumoto

Yoshio Isuda

Eiji Kashiwagi

Yoshitaka Sakanishi

Hiroshi Emoto

Hazime Horii

Youichiro Nishida

Kazuaki Nakura

Masahiro Funayama

Syojyu Kameyama

Yoshiaki Konishi

Yohei Odaka

There is provided an ophthalmic preparation comprising a fat emulsion containing flurbiprofen or its derivative such as ester as an active ingredient.

Flurbiprofen derivative ophthalmic preparation

A method of producing immunoglobulin preparations for intravenous injection which starts with an immunoblobulin-containing fraction and comprises the treatment steps of:

Method of producing immunoglobulin preparations for intravenous injection

A therapeutic and prophylactic agent for peptic ulcers which contains as an active ingredient a compound of the general formula (I): ##STR1## wherein R.sub.1 represents hydrogen or .dbd.O; R.sub.2 represents hydrogen or --OR.sub.5 ; R.sub.3 represents hydrogen or --OR.sub.5 ; R.sub.4 represents --OR.sub.7 in the case of the absence of double bond; R.sub.5, R.sub.6 and R.sub.7 each represents hydrogen or an organic residue;

Therapeutic and prophylactic agents for peptic ulcer

A DNA sequence of the yeast glyceraldehyde-3-phosphate dehydrogenase (GAP-DH) promoter and a process for preparing a heterologous protein utilizing said DNA sequence as a promoter are disclosed, said GAP-DH promoter comprising a region upstream of an initiator codon of the GAP-DH protein up to -164 bp as a minimum unit. Since the GAP-DH promoter is small in size, a physiologically active substance can be expressed in yeasts effectively and recombination of DNA can be simplified.

Yeast promoter truncated GAP-DH

A monoclonal antibody is described, having a specific reactivity with a cancer-associated antigen selected from pancreas cancer-associated antigen, intestinum crassum cancer-associated antigen and hepatoma-associated antigen and has the following characteristics:

Monoclonal antibody, process for preparing same, reagent for detecting

A method of producing a heterologous protein in yeast is disclosed, which comprises transforming a yeast Saccharomyces cerevisiae with recombinant DNA comprising a promoter selected from the group consisting of a yeast promoter or a hybrid promoter derived from a yeast promoter, particularly a hybrid promoter containing the enhancer region of SV40 virus, and a gene coding for a heterologous protein such as HBsAg and Pre S-HBsAg, particularly full length Pre S-HBsAg culturing, the resulting transformed cells to express the gene coding the heterologous protein, and isolating the heterologous protein from the cultured medium. GAP-DH and PH05 promoters and miniaturized ones can be used as the yeast promoter. The expression of the full length Pre S-HBsAg is carried out in the same expression system as that for 2nd or 3rd Pre S-ABsAg.

Yeast promoter and process for preparing heterologous protein

A therapeutic and prophylactic agent for peptic ulcers which contains as an active ingredient a compound of the general formula (I): ##STR1## wherein R.sub.1 represents hydrogen or =O; R.sub.2 represents hydrogen or --OR.sub.5 ; R.sub.3 represents hydrogen or --OR.sub.6 ; R.sub.4 represents --OR.sub.7 in the case of the absence of double bond; R.sub.5, R.sub.6 and R.sub.7 each represents hydrogen or an organic residue;

A fat emulsion containing a prostaglandin E.sub.1 alkyl ester represented by the general formula ##STR1## wherein R denotes an alkyl group having 1 to 30 carbon atoms. The fat emulsion can be administered intravenously, has a long half-life of its effective ingredient, prostaglandin E.sub.1 alkyl ester, in the living body as well as a focus selectivity.

Fat emulsion containing prostaglandin

A pharmaceutical composition comprises a benzoyl urea compound having the formula: ##STR1## wherein X is a nitro group, Y is a chlorine atom, Z.sub.2 is a hydrogen atom, Z.sub.1 is a halogen atom, and A is a nitrogen atom, and at least one member selected from the group consisting of a cyclodextrin, a polyethylene glycol and a refined oil.

Readily absorbable pharmaceutical composition

A method for purifying factor VIII complex comprising: (A) absorbing an impure extract containing factor VIII complex on a water-insoluble carrier, and (B) recovering factor VIII complex in the unadsorbed fractions, wherein said water-insoluble carrier contains as a ligand a group represented by the formula (I) or (II):

Method of purifying factor VIII

A recombinant plasmid wherein at least two DNA fragments containing a Baker gene and a Charlie gene of the yeast 2 .mu.m circular plasmid are incorporated into a plasmid containing genes encoding a physiologically active substance is disclosed. Also, a strain transformed by the recombinant plasmid is disclosed.

Recombinant plasmid and microbial strain transformed by said plasmid

A lipoxygenase inhibitor comprising as active ingredient a substituted styrene derivative having a radical of the general formula ##STR1## wherein X denotes a hydroxyl group or a lower alkoxy group and q is an integer of 2 or 3, and containing carbon atoms in total of at least 8.

Lipoxygenase inhibitor

Virus-contaminated immunoglobulin can be virus-inactivated by heating it in a substantially dry state at a temperature of 30.degree. to 100.degree. C. for a period of time sufficient for inactivating virus with maintaining original activity of the immunoglobulin. The addition of glycine, sodium chloride, sodium acetate, polyethylene glycol, albumin or mannitol enhances the effect and gives good solubility and good state to the solution of the virus-inactivated immunoglobulin.

Process for the virus-inactivation of immunoglobulin

A novel compound of the formula, ##STR1## wherein R denotes a lower perfluoroalkyl group, l is an integer of 3 or 4, n+m is an integer of 2 or 3, provided that n may be zero, and at least one of ring A and ring B may be substituted by a lower perfluoroalkyl group, prepared by reacting the corresponding perhydro compound with fluorine is useful as a material capable of carrying oxygen in an aqueous emulsion for lifesaving a patient suffering from massive hemorrhage and for preserving internal organs in transplantation.

Perfluoro compounds

A process for the purification of HBsAg is disclosed, which comprises adsorbing specifically on a carrier, in the presence of an inorganic salt in an amount of 5 to 25 W/V %, an HBsAg obtained by gene engineering.

Process for the purification of HBsAg

Growing community of inventors

Kyoto, Japan

Tadakazu Suyama